Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
13 studies found for:    CAT-354
Show Display Options
Rank Status Study
1 Completed A Study to Assess Bioavailability and Pharmacokinetics of CAT 354
Condition: Healthy
Intervention: Drug: CAT-354
2 Completed Study to Evaluate the Safety and Efficacy of CAT-354
Condition: Asthma
Interventions: Drug: CAT-354;   Other: Placebo
3 Completed A Study to Assess the Safety and Immunogenicity of the Drug CAT-354 in Healthy Japanese Subjects
Condition: Healthy
Interventions: Drug: CAT-354;   Drug: CAT 354
4 Terminated A Study to Assess the Efficacy, Safety,and Tolerability of CAT-354
Condition: Asthma
Interventions: Drug: CAT-354;   Drug: Placebo
5 Completed A Study to Assess the Safety and Tolerability of Multiple Doses of Multi-Level of a Drug in Subjects With Moderate Asthma
Condition: Asthma
Interventions: Drug: CAT-354-0602;   Drug: Placebo
6 Completed A Trial to Investigate the Pharmacokinetics of Tralokinumab in Adolescents, a Product Under Investigation for the Treatment of Asthma
Condition: Asthma
Intervention: Biological: Cohort 1
7 Recruiting D2212C00002 J-Phase II Study
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Biological: tralokinumab cohort 1;   Biological: tralokinumab cohort 2;   Other: Placebo
8 Completed Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: tralokinumab;   Drug: placebo
9 Completed A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Asthma
Condition: Asthma
Intervention: Drug: Tralokinumab
10 Recruiting A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Biological: Tralokinumab;   Other: Placebo
11 Completed
Has Results
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Condition: Psoriasis
Interventions: Drug: CP 690,550 5 mg;   Drug: CP 690,550 10 mg;   Biological: Etanercept 50 mg;   Other: Placebo
12 Completed
Has Results
Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.
Condition: Rheumatoid Arthritis
Interventions: Biological: Adalimumab;   Drug: Placebo
13 Completed
Has Results
Telmisartan 80mg+Hydrochlorothiazide (HCTZ) 25 mg in Hypertension: an Observational Study
Condition: Hypertension

Indicates status has not been verified in more than two years